Avalon AI

Detecting Dementia before it happens

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location London, United Kingdom
  • Currency GBP
  • Founded November 2015
  • Employees 2
  • Incorporation Type Other
  • Website avalonai.com

Company Summary

Our Machine Learning algorithms analyse brain MRIs to predict which patients with Mild Cognitive Impairment (MCI) will progress to Dementia within one year. With our tech, pharmaceutical companies can run much cheaper and shorter clinical trials because they can enrol only the MCI patients that are likely to transition soon.

Team

  • Alejandro (Sasha) Vicente Grabovetsky is a Cognitive Neuroscientist with a BA (3rd in his year) and PhD from Cambridge and has done a PostDoc at the Donders Centre in Nijmegen (NL), which are among the very top neuroimaging labs in the world, specialising in the Neuroimaging of short and long-term memory. He has contributed to leading automatic analysis neuroimaging packages and been awarded 5 prizes in science communication.

  • Co-founder, CTO

    Olivier van den Biggelaar is a Software Engineer with a Master in Engineering, a Master in Business Management and a PhD in Machine Learning from the University of Brussels. He has spent 3 years in industry building ML systems including a recommendation engine for a large video streaming platform. He has won the top 2 prizes (10,000€) in a Belgian business plan competition.

Advisors

  • Chris Mairs
    Unconfirmed

Previous Investors

  • Entrepreneur First
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free